This site became the new on June 19th. Learn more.
Show more Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu
Give us feedback

ENterogermina® (Bacillus Clausii) In the manaGeMent of diarrheA in Children (ENIGMA)

This study has been completed.
Information provided by:
Sanofi Identifier:
First received: April 5, 2007
Last updated: January 20, 2009
Last verified: January 2009


  • To demonstrate the efficacy of Enterogermina® in reducing the duration of acute diarrhea in children


  • To evaluate the safety of Enterogermina® in acute diarrhea in Indian children

Condition Intervention Phase
Gastroenteritis Drug: Bacillus Clausii Other: Oral rehydration therapy Phase 3

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Phase III Comparative Study to Assess the Efficacy and Safety of Oral Rehydration Therapy (ORT) in Combination With Spores of Bacillus Clausii (Enterogermina)Versus ORT Alone, Administered for 5 Days With the Treatment of Acute Diarrhea in Children.

Resource links provided by NLM:

Further study details as provided by Sanofi:

Primary Outcome Measures:
  • Reduction in duration of diarrhea [ Time Frame: Throughout the treatment period ]
  • Incidence of adverse events [ Time Frame: Throughout the study period ]

Secondary Outcome Measures:
  • Mean number of stools per day [ Time Frame: Throughout the treatment period ]
  • Effect on consistency of stools [ Time Frame: Throughtout the treatment period ]
  • Vomiting episodes per day [ Time Frame: Throughout the treatment period ]
  • Requirement of unscheduled intravenous transfusion [ Time Frame: Throughout the study period ]
  • Need for hospitalization [ Time Frame: Throughout the treatment period ]

Enrollment: 264
Study Start Date: March 2007
Primary Completion Date: December 2007 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Active Comparator: 1
Administration of oral rehydration therapy with Bacillus clausii probiotic strain (1 vial twice daily, each vial containing 2 billion spores of Bacillus clausii)
Drug: Bacillus Clausii
For 5 days
Placebo Comparator: 2
Administration of Oral rehydration therapy
Other: Oral rehydration therapy
For 5 days


Ages Eligible for Study:   6 Months to 5 Years   (Child)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Non hospitalised infants and children attending clinic/outpatients with acute diarrhea (>3 liquid or watery stools occurring in a 24-hour period) of less than 48 hours duration

Exclusion Criteria:

  • History of presence of blood, pus, or mucus in stools
  • Severe dehydration (World Health Organization criteria)
  • Severely malnourished patients
  • Treatment with antibiotics, probiotics, or prebiotics within a period of 2 weeks before enrolment
  • History of conditions known to producing immunodeficiency (Acquired Immune Deficiency Syndrome, other congenital immunodeficiency syndrome, drug therapy with steroids, anticancer drugs etc)
  • Known hypersensitivity to Bacillus clausii or other probiotics.

The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.

  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00457353

Mumbai, India
Sponsors and Collaborators
Study Director: Shah Pratik Sanofi
  More Information

Responsible Party: Medical Affairs Study Director, sanofi-aventis Identifier: NCT00457353     History of Changes
Other Study ID Numbers: ENTER_L_01486
Study First Received: April 5, 2007
Last Updated: January 20, 2009

Additional relevant MeSH terms:
Signs and Symptoms, Digestive
Signs and Symptoms
Gastrointestinal Diseases
Digestive System Diseases processed this record on September 21, 2017